stremcentrx

Showing 1 posts of 1 posts found.

abbvie_0

AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, acquisition, rova-t, stremcentrx, takeover

AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), …

Latest content